44 results on '"Piccart, M."'
Search Results
2. Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study
3. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
4. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials
5. Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172).
6. Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling.
7. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
8. Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women.
9. Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.
10. CD10 expression and risk of relapse in DCIS
11. Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial
12. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors
13. Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes
14. Investigating the predictive value of topoisomerase II alpha (TOP2A) gene, mRNA and protein levels in anthracycline-treated estrogen receptor (ER) negative breast cancer (BC) patients
15. A substantial change in breast cancer (BC) biology arises after 50 years old regardless of patient (pt) menopausal status
16. Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: Tailoring treatment in hormone responsive breast cancer
17. HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy
18. Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent
19. Oxaliplatin and 5-fluorouracil in heavily pretreated patients with ovarian carcinoma: A well tolerated and efficient treatment
20. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients
21. Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC)
22. Clinical validation of in vitro drug sensitivity microarray data: Regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00–01)
23. Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995
24. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC)
25. Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2–98 Trial at 5 years median follow-up (MFU)
26. Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer
27. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer
28. Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring
29. ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer
30. Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of “grade 2” tumors
31. A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer
32. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
33. Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts)
34. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
35. Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial
36. The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET)
37. Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors
38. Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer
39. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
40. Regarding the dilemma of adjuvant therapy in postmenopausal patients with node-positive, estrogen receptor-positive breast cancer: are we better informed?
41. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
42. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam.
43. Successful re-treatment with taxol after major hypersensitivity reactions.
44. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.